Arrhythmias & electrophysiology
Arrhythmogenic substrate elimination for safe testosterone therapy in symptomatic Brugada syndrome patients
Authors' conclusion
RFA can be considered as a therapeutic option in symptomatic BrS patients with a high-risk profile who cannot discontinue TRT, being essential for restoring their normal physiology or preserving their sexual identity.
Study context
- Population
- Symptomatic Brugada Syndrome (BrS) patients with arrhythmic events while on testosterone replacement therapy
- Participants
- 2 cases
Main finding
As reported in the abstract
- Abnormal areas of prolonged and fragmented electrograms in right ventricular (RV) outflow tract and anterior wall on epicardial mapping, in both cases
- Abnormalities completely abolished by radiofrequency ablation (RFA)
- Persistent ECG normalisation and freedom from ventricular arrhythmias at follow-up despite ongoing testosterone replacement therapy (TRT), in both patients
Original publication
Arrhythmogenic substrate elimination for safe testosterone therapy in symptomatic Brugada syndrome patients. Europace. Published 1 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →